Ureaplasma parvum undergoes selection in utero resulting in genetically diverse isolates colonizing the chorioamnion of fetal sheep by Dando, Samantha et al.
1 
 
Ureaplasma parvum undergoes selection in utero resulting in genetically diverse isolates 
colonising the chorioamnion of fetal sheep 
Running Title: In utero selection of U. parvum variants 
Summary Sentence: The chorioamnion selects for different ureaplasma sub-types within a 
non-clonal population during chronic intrauterine infection; ureaplasmas isolated from 
chorioamnion tissue contained highly polymorphic 23S rRNA gene sequences. 
Keywords: ureaplasma, amniotic fluid, chorioamnion, ribosomal RNA, minimum inhibitory 
concentration, ovine model. 
 
Samantha J. Dando 
1*
, Ilias Nitsos 
2#
, Graeme R. Polglase 
2#
, John P. Newnham 
2
, Alan H. 
Jobe 
3
, Christine L. Knox 
1 
 
1
Institute of Health and Biomedical Innovation, Faculty of Health, Queensland University of 
Technology, Brisbane, Queensland, Australia. 
2School of Women’s and Infants’ Health, The University of Western Australia, Perth, 
Western Australia, Australia. 
3
Department of Neonatology and Pulmonary Biology, Cincinnati Children’s Hospital 
Medical Center, University of Cincinnati, Cincinnati, Ohio, USA. 
 
1
This work was funded by the National Health and Medical Research Council of Australia 
(Grant Numbers 458577, 37601600 and 1010315).  
2 
 
*
Corresponding author (current affiliation): Dr Samantha Dando, s.dando@griffith.edu.au, 
Institute for Glycomics, Griffith University, Queensland, Australia.  
#
Current affiliation: The Ritchie Centre, Monash Institute of Medical Research & Department 
of Obstetrics and Gynaecology, Monash University, Clayton, Victoria, Australia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
Abstract 1 
Ureaplasmas are the microorganisms most frequently isolated from the amniotic fluid of 2 
pregnant women and can cause chronic intrauterine infections. These tiny bacteria are 3 
thought to undergo rapid evolution and exhibit a hypermutatable phenotype; however, little is 4 
known about how ureaplasmas respond to selective pressures in utero. Using an ovine model 5 
of chronic intra-amniotic infection, we investigated if exposure of ureaplasmas to sub-6 
inhibitory concentrations of erythromycin could induce phenotypic or genetic indicators of 7 
macrolide resistance. At 55 days gestation, 12 pregnant ewes received an intra-amniotic 8 
injection of a non-clonal, clinical U. parvum strain, followed by: (i) erythromycin treatment 9 
(IM, 30 mg/kg/day, n=6); or (ii) saline (IM, n=6) at 100 days gestation. Fetuses were then 10 
delivered surgically at 125 days gestation. Despite injecting the same inoculum into all ewes, 11 
significant differences between amniotic fluid and chorioamnion ureaplasmas were detected 12 
following chronic intra-amniotic infection. Numerous polymorphisms were observed in 13 
domain V of the 23S rRNA gene of ureaplasmas isolated from the chorioamnion (but not the 14 
amniotic fluid), resulting in a mosaic-like sequence. Chorioamnion isolates also harboured 15 
the macrolide resistance genes erm(B) and msr(D) and were associated with variable 16 
roxithromycin minimum inhibitory concentrations. Remarkably, this variability occurred 17 
independently of exposure of ureaplasmas to erythromycin, suggesting that low-level 18 
erythromycin exposure does not induce ureaplasmal macrolide resistance in utero. Rather, the 19 
significant differences observed between amniotic fluid and chorioamnion ureaplasmas 20 
suggest that different anatomical sites may select for ureaplasma sub-types within non-clonal, 21 
clinical strains. This may have implications for the treatment of intrauterine ureaplasma 22 
infections.  23 
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Introduction 24 
The human ureaplasmas (Ureaplasma parvum and Ureaplasma urealyticum) are among the 25 
smallest self-replicating bacteria, typically ranging in size from 100 nm to 1 µm [1]. They can 26 
be isolated from the mucosal surfaces of the vagina or cervix in 40 – 80% of sexually active 27 
females [2] and are the most frequently isolated microorganisms from infected amniotic 28 
fluids and placentas [3-6]. Although amniotic fluid contains a number of 29 
bacteriostatic/bacteriocidal components [7], ureaplasmas have been detected in the amniotic 30 
fluid of pregnant women as early as the 16
th
 week of pregnancy (in the presence of intact fetal 31 
membranes) and have been reported to persit for as long as two months [8]. Furthermore, in a 32 
sheep model of intra-amniotic infection, we demonstrated that ureaplasmas can colonise the 33 
amniotic fluid for up to 85 days [9]. Although often clinically silent, intra-amniotic 34 
ureaplasma infections stimulate a pro-inflammatory host response [9, 10] and are associated 35 
with histological chorioamnionitis, funisitis and preterm birth. Ureaplasmas may also 36 
colonise the fetus in utero, or be vertically transmitted to the infant at birth, and are associated 37 
with neonatal diseases including bronchopulmonary dysplasia, pneumonia, sepsis and 38 
meningitis [11, 12].  39 
Eradication of intra-amniotic ureaplasma infections by antimicrobial treatment is thought to 40 
improve pregnancy outcomes and reduce neonatal morbidity and mortality [13, 14]. 41 
Erythromycin (a 14-membered lactone ring macrolide) is routinely administered to pregnant 42 
women for the treatment of intra-amniotic infections and preterm, prelabour rupture of 43 
membranes. However, this treatment may be ineffective [15, 16] as there is minimal placental 44 
transfer of erythromycin from the maternal circulation to the amniotic fluid. In humans, the 45 
placental transfer of erythromycin is as low as 3% [17], suggesting that microorganisms 46 
within the amniotic fluid might only be exposed to low levels of antimicrobials. In an ovine 47 
model of intra-amniotic ureaplasma infection, we reported that standard-dose maternal 48 
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erythromycin treatment achieved low concentrations (<10 – 76 ng/mL) in the amniotic fluid 49 
and did not eradicate infection [18].  50 
Exposure of bacteria to non-lethal concentrations of antimicrobials may promote 51 
antimicrobial resistance, which can occur by target site modification, drug efflux pumps, or 52 
drug inactivation mediated by short peptides [19]. Mechanisms of macrolide resistance that 53 
have been identified in ureaplasmas include target site modification via mutations in the 23S 54 
rRNA gene and ribosomal protein L4 and L22 genes [20-22]. The lactone ring of macrolide 55 
antimicrobials interacts hydrophobically with the crevice formed by bases 2057, 2058 and 56 
2059 (Escherichia coli numbering) of the 23S rRNA gene; therefore a mutation in any of 57 
these nucleotides may inhibit macrolide binding. Similarly, point mutations in ribosomal 58 
protein L4 and L22 genes may also allosterically affect macrolide binding [19]. In addition, 59 
erythromycin-ribosome methylase (erm) genes, which post-translationally methylate 60 
nucleotide 2058 of domain V of the 23S rRNA gene to inhibit macrolide binding via steric 61 
hindrance, have been reported in ureaplasmas and may be associated with phenotypic 62 
resistance [23]. Macrolide resistance may also occur by the activity of drug efflux pumps 63 
such as the macrolide streptogramin resistance (msr) genes, which export antimicrobials out 64 
of the bacterial cell. Previously, Lu et al. [23] detected msr(A), msr(B) and msr(D) subtypes 65 
in Ureaplasma spp. and suggested that they may be associated with ureaplasmal resistance to 66 
macrolides and/or lincosamides.  67 
Members of the Mycoplasmataceae family with very small genomes, such as the Ureaplasma 68 
spp., exhibit a hypermutatable phenotype and may undergo rapid evolution [24, 25]. Indeed, 69 
ureaplasmas undergo significant genetic variability associated with: (i) size/phase variation of 70 
surface-exposed antigens [26-30]; (ii) the presence of hypervariable plasticity zones 71 
functioning as putative pathogenicity islands [31] and (iii) horizontal gene transfer and 72 
proposed recombination events resulting in genetic mosaics [32, 33]. Furthermore, point 73 
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mutations in ureaplasmal 23S rRNA, ribosomal protein L4 and L22 genes can be induced in 74 
vitro by passaging isolates in broth medium containing sub-inhibitory concentrations of 75 
macrolide antimicrobials [22]. However, to the best of our knowledge, the effects of low-76 
level antimicrobial exposure on ureaplasmas have not been investigated in vivo.  77 
Using an ovine model of chronic intra-amniotic infection, we tested if U. parvum colonising 78 
the amniotic fluid and chorioamnion of pregnant sheep underwent genetic variation following 79 
exposure to selective antimicrobial pressure. Specifically, we investigated if exposure of 80 
ureaplasmas to sub-inhibitory concentrations of erythromycin in utero could induce genetic 81 
markers of macrolide resistance.  By sequencing regions of the ureaplasmal 23S rRNA gene 82 
and performing PCRs to detect macrolide resistance genes, we observed significant genetic 83 
variability within chorioamnion ureaplasmas following chronic, intra-amniotic infection.  84 
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Materials and Methods  85 
Ethics statement 86 
All experimental procedures involving animals were performed in accordance with the 87 
“Australian code of practice for the care and use of animals for scientific purposes” (National 88 
Health and Medical Research Council of Australia) and were approved by the Animal Ethics 89 
Committee of The University of Western Australia. 90 
Animal model and specimen collection 91 
The inoculum used for intra-amniotic injection was a low-passage, erythromycin-susceptible, 92 
U. parvum serovar 3 isolate (442S) that was originally isolated from the semen of an infertile 93 
man attending the Wesley IVF Service (Brisbane, Queensland). Isolate 442S was selected for 94 
this study as it was a non-clonal, clinical strain containing a mixture of ureaplasma subtypes 95 
that were adherent and non-adherent to the surface of spermatozoa. A non-clonal strain, as 96 
opposed to a clonal ureaplasma strain that had been cloned and filtered in vitro, was chosen 97 
to closely model ureaplasmas isolated from natural infections. Ureaplasmas for injection were 98 
prepared as previously described and diluted to 2 x 10
4
 CFU in PBS prior to intra-amniotic 99 
injection [34].  100 
The samples analysed in this study were collected from a previously described experiment 101 
[18]. Briefly, at 55 days gestation (term = 150 days gestation), 12 date-mated Merino ewes 102 
bearing single fetuses received a 2 mL intra-amniotic injection of U. parvum 442S [34]. At 103 
100 days gestation, ewes were randomly assigned to receive erythromycin treatment (Up/E 104 
group; n = 6) or saline (Up group; n = 6). Ewes that received erythromycin treatment were 105 
injected intra-muscularly with 500 mg of erythromycin (Abbot Australasia, Kurnell, New 106 
South Wales) three times daily for four days (100 – 104 days gestation), resulting in a total 107 
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dose of 30 mg/kg/day. Additional antibiotics were not added to the supplementary feed given 108 
to pregnant ewes, nor did animals receive antimicrobial treatment as part of on-going 109 
veterinary care. Preterm fetuses were surgically delivered at 125 days gestation [18]. Samples 110 
of amniotic fluid and chorioamnion were aseptically collected and stored at -80 °C for 111 
subsequent analysis.  112 
Ureaplasma culture 113 
Ureaplasmas were cultured from amniotic fluid and chorioamnion samples collected from 114 
each animal. Thawed chorioamnion tissue (0.1 g) was homogenised in 1.5 mL of 10B 115 
medium [35] using a mini beadbeater 8-cell disrupter (Daintree Scientific, St Helens, 116 
Tasmania). Homogenised chorioamnion and amniotic fluid samples were then cultured in 117 
10B medium [36] and positive cultures were stored at -80 °C for further analysis.  118 
23S rRNA, ribosomal protein L4 and ribosomal protein L22 PCR and sequencing  119 
To detect polymorphisms within genes associated with macrolide resistance, PCRs targeting 120 
domain II and domain V of the 23 rRNA gene, ribosomal protein L4 gene and ribosomal 121 
protein L22 gene were performed on the ureaplasma isolates from the amniotic fluid and 122 
chorioamnion. DNA was extracted from first passage cultures in 10B broth using previously 123 
described methods [37]. The PCR assays were performed in 50 µL reaction mixtures 124 
containing: 100 µM of dNTP mix (Roche Diagnostics, Castle Hill, New South Wales), 1 x 125 
PCR buffer (Invitrogen, Mt Waverley, Victoria), 1.5 mM of MgCl2 (Invitrogen), 0.5 µM of 126 
each primer (Sigma Aldrich, Castle Hill, New South Wales; primer sequences are shown in 127 
Table 1), 2.5 U of Platinum Taq Polymerase (Invitrogen) and PCR-grade H2O. PCR cycling 128 
involved initial denaturation at 94 °C for 15 minutes, followed by 35 cycles of denaturation at 129 
94 °C for 1 minute, primer annealing at 56 °C for 1 minute, extension at 72 °C for 2 minutes, 130 
plus a final extension at 72 °C for 15 minutes.  131 
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PCR products from U. parvum 442S and representative amniotic fluid (n = 5) and 132 
chorioamnion (n = 4) strains were purified using the High Pure PCR Product Purification Kit 133 
(Roche). Sequencing reactions were performed by the Australian Genome Research Facility 134 
(St Lucia, Queensland). Sequence data were trimmed to obtain sequences of a uniform length 135 
and then aligned using Geneious Pro version 5.6.5. Partial 23S rRNA sequences from 136 
representative amniotic fluid and chorioamnion ureaplasma isolates were deposited in 137 
GenBank (National Center for Biotechnology Information, 2013) under the accession 138 
numbers JF521483, JF521484, JF521485 and JF521486. 139 
erm(B) and msr gene PCR 140 
PCRs were performed to detect selected genes associated with macrolide resistance (erm(B), 141 
msr(A), msr(B), msr(C) and msr(D)) [23, 38-40]. These assays were performed on isolates 142 
selected for 23S rRNA and ribosomal protein L4 and L22 gene sequencing. PCRs were 143 
performed in 50 µL volumes as described above, using primers shown in Table 1. PCR 144 
reactions were performed using cycling conditions described by Lu et al. [23]; however, 145 
initial denaturation and final elongation steps were modified to 94 °C for 15 minutes and 72 146 
°C for 15 minutes respectively.  147 
Minimum inhibitory concentration 148 
The minimum inhibitory concentrations (MICs) of erythromycin (Sigma Aldrich), 149 
roxithromycin (Sigma Aldrich) and azithromycin (Pfizer, West Ryde, New South Wales) 150 
were determined for ureaplasmas isolated from amniotic fluid and chorioamnion samples at 151 
125 days gestation. Isolates to be tested were thawed and diluted to a standardised 152 
concentration of 1 x 10
4
 CFU/mL in 10B broth. MICs were determined using standard broth 153 
microdilution assays [41, 42] and interpreted according to defined CLSI breakpoints [42]. 154 
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Each antibiotic was tested in triplicate and MIC results are expressed as the mean value of the 155 
three experiments.  156 
Statistical analysis 157 
Statistical analyses were performed using Graph Pad Prism version 5.0. A two-tailed Fisher’s 158 
exact test was used to compare the proportion of amniotic fluid and chorioamnion ureaplasma 159 
isolates harbouring macrolide resistance genes. MIC data were compared between Up and 160 
Up/E groups using independent, two-tailed t tests.  161 
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Results 162 
Intra-amniotic ureaplasmas caused chronic intrauterine infection 163 
Injection of U. parvum into the amniotic fluid of pregnant ewes at 55 days gestation resulted 164 
in chronic intrauterine infection. At 125 days gestation, ureaplasmas were isolated from 6//6 165 
amniotic fluid samples (100%) and 4/6 chorioamnion samples (67%) collected from the Up 166 
group. Maternal erythromycin treatment (Up/E group) did not eliminate ureaplasma 167 
colonisation within the amniotic fluid (6/6 (100%) culture positive) and chorioamnion (4/6 168 
(67%) culture positive) at 125 days gestation. Quantitative bacterial cultures from these 169 
amniotic fluid and chorioamnion samples were reported in a previous publication [18]. First 170 
passage cultures were stored at -80 °C and used for DNA extraction and MIC testing. 171 
23S rRNA gene sequence variability in ureaplasmas isolated from the chorioamnion 172 
The maternal administration of erythromycin resulted in sub-inhibitory antimicrobial levels 173 
within the amniotic fluid in pregnant sheep [18]. To determine if ureaplasmas exposed to sub-174 
inhibitory concentrations of erythromycin in utero demonstrated genetic markers of 175 
antimicrobial resistance, PCR was performed to amplify domain II and domain V of the 23S 176 
rRNA gene, and the genes encoding ribosomal protein L4 and ribosomal protein L22 (data 177 
not shown). Amplicons from amniotic fluid and chorioamnion ureaplasma isolates, and U. 178 
parvum isolate 442S were then sequenced. Within each of the sequenced regions, U. parvum 179 
isolate 442S shared 100% sequence identity with the U. parvum serovar 3 reference strain 180 
(ATCC 700970; Genbank accession number AF222894). No sequence polymorphisms were 181 
detected in any of the ureaplasmas, which were isolated from amniotic fluid samples, across 182 
any of the targeted regions of the 23S rRNA gene and the L4 and L22 ribosomal protein 183 
genes. Hence, all amniotic fluid isolates shared 100% sequence identity with the U. parvum 184 
serovar 3 reference strain and isolate 442S (the inoculum). 185 
12 
 
Conversely, significant genetic variability was detected within all ureaplasma isolates from 186 
the chorioamnion, when compared to amniotic fluid ureaplasma isolates, U. parvum ATCC 187 
700970 and U. parvum 442S (Table 2). These polymorphisms occurred independently of 188 
exposure to erythromycin as they were detected in chorioamnion isolates from both the Up 189 
and Up/E groups. The regions of genetic variability were localised within domain V of the 190 
23S rRNA gene, specifically within the regions amplified by PCR primers MH23S-191 
11/MP23S-22 and MH23S-9/MP23S-23. Within the region amplified by the primer pair 192 
MH23S-11/MP23S-22, 72 identical polymorphisms, 5 insertions and 5 deletions (out of 230 193 
sequenced nucleotides) were detected in each chorioamnion ureaplasma isolate. Similarly, 194 
within the region of domain V of the 23S rRNA gene amplified by PCR primer MH23S-195 
9/MP23S-23, 36 identical polymorphisms (out of 200 nucleotides) were detected. Within 196 
these polymorphic regions, a higher G+C content were also observed (Table 2). Gene 197 
alignments demonstrating the significant sequence variability between chorioamnion and 198 
amniotic fluid ureaplasma strains are shown in Figure 1 (MH23S-11/MP23S-22 amplicon) 199 
and Figure 2 (MH23S-9/MP23S-23 amplicon).  200 
Despite the large number of polymorphisms detected in chorioamnion ureaplasma strains, 201 
specific nucleotides that were previously associated with macrolide resistance in ureaplasmas 202 
and other bacteria (nucleotides G2056, G2057 and A2058 of domain V of the 23S rRNA 203 
gene, E. coli numbering [22]; and C2243, U. urealyticum numbering [21]) remained 204 
conserved. No polymorphisms were detected in domain II of the 23S rRNA gene or 205 
ribosomal proteins L4 and L22.  206 
Macrolide resistance genes were detected in ureaplasmas isolated from chorioamnion 207 
tissue 208 
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The macrolide resistance gene erm(B) was not detected in any ureaplasmas isolated from the 209 
amniotic fluid, but was present in U. parvum 442S and 100% of ureaplasmas isolated from 210 
the chorioamnion (p = 0.008; Figure 3A). Of the four tested msr gene subtypes, msr(D) was 211 
the only gene detected in the ureaplasma isolates (Figure 3B). msr(D) was detected in U. 212 
parvum 442S, 2/5 amniotic fluid ureaplasma isolates (40%) and 100% of chorioamnion 213 
ureaplasma isolates (p < 0.05). The presence of macrolide resistance genes occurred 214 
independently of exposure to erythromycin, as erm(B) and msr(D) genes were detected in 215 
ureaplasmas from both the Up and Up/E groups.  216 
23S rRNA genetic variability and erm(B) and msr(D) genes were not associated with 217 
phenotypic resistance to macrolide antimicrobials 218 
The inoculum strain used for this animal study, U. parvum strain 442S, was susceptible to 219 
erythromycin, azithromycin and roxithromycin, with MIC values of 0.13 mg/L, 0.5 mg/L and 220 
0.5 mg/L respectively. Ureaplasmas isolated from the amniotic fluid after 125 days gestation 221 
also demonstrated susceptibility to erythromycin, azithromycin and roxithromycin (Table 3). 222 
The MICs of these three antimicrobials were not different when tested against amniotic fluid 223 
ureaplasmas isolated from the Up group and the Up/E group (p > 0.05).  224 
Although ureaplasmas isolated from the chorioiamnion demonstrated: (i) significant genetic 225 
variability within domain V of the 23S rRNA gene, and (ii) the presence of erm(B) and 226 
msr(D) resistance genes, these isolates were not phenotypically resistant to the tested 227 
macrolide antimicrobials (Table 3). The MICs of erythromycin and azithromycin against 228 
ureaplasmas isolated from the chorioamnion were low, ranging from 0.06 – 0.25 mg/L, 229 
whereas the MICs of roxithromycin were variable against chorioamnion ureaplasmas, 230 
ranging from 0.13 – 5.33 mg/L. However, according to the defined CLSI breakpoints, none 231 
of the chorioamnion ureaplasma isolates were resistant to roxithromycin. The MICs of 232 
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erythromycin, azithromycin and roxithromycin were not statistically different between 233 
ureaplasmas isolated from the chorioamnion from the Up group and the Up/E group (p > 234 
0.05).  235 
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Discussion 236 
We investigated whether low-level erythromycin exposure could induce genetic markers of 237 
macrolide resistance in ureaplasmas isolated from the amniotic fluid and chorioamnion of 238 
pregnant sheep at 125 days gestation. Sub-inhibitory erythromycin concentrations were 239 
achieved in the amniotic fluid via maternal intra-muscular erythromycin treatment at 100 – 240 
104 days gestation [18]. Previous studies have suggested that ureaplasmas are highly variable 241 
and undergo rapid evolution [24, 25]; therefore we hypothesised that the application of 242 
selective antimicrobial pressure for a short period of time (four days) may be sufficient to 243 
generate genetic variants. We assessed this by performing PCR and sequencing of domain II 244 
and domain V of the ureaplasmal 23S rRNA gene and ribosomal protein L4 and L22 genes. 245 
Mutations in these genes were previously associated with macrolide resistance in 246 
ureaplasmas [20-22]. We detected significant genetic variability, including nucleotide 247 
substitutions, insertions and deletions, within domain V of the 23S rRNA gene; however, this 248 
variability did not occur in response to erythromycin treatment. Rather, genetic variability 249 
within the 23S rRNA gene was detected exclusively in ureaplasmas isolated from the 250 
chorioamnion following chronic intrauterine infection and was present in ureaplasmas 251 
isolated from both the treatment and the control group animals.  252 
Genetic diversity was detected within two regions of domain V of the 23S rRNA gene, 253 
amplified by two separate primer pairs. U. parvum possesses two ribosomal operons, both of 254 
which were amplified simultaneously by the primers used in this study. Sequence 255 
chromatograms did not reveal double peaks at any loci, indicating that both copies of the 23S 256 
rRNA gene were identical. Marques et al. [43] previously reported intraspecific sequence 257 
variation of the 16S rRNA gene of the bovine pathogen U. diversum. In their study of 34 field 258 
isolates, four hypervariable regions within the 16S rRNA gene were identified and within 259 
these regions 44 polymorphisms were detected. Furthermore, an isolate with only 88% 260 
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sequence similarity to the U. diversum 16S rRNA reference sequence was identified. In the 261 
present study, across the two variable regions of domain V of the 23S rRNA gene, 262 
ureaplasmas isolated from the chorioamnion shared only 78% sequence similarity with the U. 263 
parvum 442S inoculum strain.  264 
Due to: (i) the presence of identical polymorphisms in chorioamnion ureaplasma strains and 265 
(ii) the increased G+C content of these variable regions, we propose that these regions of 266 
genetic variability may represent fragments transferred by horizontal gene transfer (HGT). 267 
Previous studies have demonstrated that ureaplasmas undergo extensive HGT resulting in 268 
genetic mosaics, which arise from proposed recombination events [32, 33]. U. parvum isolate 269 
442S, the non-clonal inoculum strain, was characterised in our laboratory and found to 270 
contain a mixed population of ureaplasmas with different phenotypic properties [44]. We 271 
suggest that this strain may also contain a small population of 23S rRNA genetic variants, 272 
which were generated via previous HGT events. However, sequencing of domain V of the 273 
23S rRNA gene of isolate 442S did not detect the variant sequence nor were double peaks 274 
observed at any loci. Xiao et al. demonstrated that mixed populations of ureaplasmas could 275 
not be detected by Sanger sequencing once the DNA concentration ratio reached 9:1 [32]. 276 
Thus it is likely that the variant sequence is present only in a small, undetectable population 277 
of ureaplasmas within isolate 442S, which were subsequently selected for in the 278 
chorioamnion during chronic intra-amniotic infection.  279 
Previous studies have shown that the host immune response and host genetic background 280 
impact the outcomes of ureaplasma infection [9, 45]. Here, we have demonstrated that 281 
ureaplasma subtypes within a mixed population may be selected for at different anatomical 282 
sites within a host, which may also affect outcomes. We are unable to speculate as to which 283 
components of the chorioamnion may have resulted in the selection of the variant ureaplasma 284 
subtype; however, there are significant differences in the microenviromnent of the amniotic 285 
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fluid compared to that of the chorioamnion, which may result in different selective pressures 286 
between these anatomical sites. The amniotic fluid is a proteinaceous biological fluid, which 287 
undergoes dynamic change througout pregnancy. Early in gestation, the protein content of 288 
amniotic fluid resembles that of maternal serum (albeit at lower concentrations); however, 289 
fetal urine is a major component of amniotic fluid in the second half of pregnancy [46]. A 290 
proteomic analysis of human amniotic fluid demonstrated that amniotic fluid contained 291 
proteins that function in immune defence, cell communication/transport, metabolism, enzyme 292 
activity, signal transduction, development/cell differentiation, cell proliferation, cell 293 
organisation and others of unknown function [47]. Although comprehensive proteomic 294 
studies of the chorioamnion are lacking, the chorioamnion contains mutliple cellular layers, 295 
connective tissue and an extracellular matrix, which is composed largely of collagen [48].  296 
The source of innate immune cells within the amniotic fluid and chorioamnion have also been 297 
shown to differ – neutrophils within the chorioamnion are maternally-derived, whereas 298 
amniotic fluid neutrophils are fetal in origin [49, 50]. Interestingly, Namba et al. [50] 299 
demonstrated that sulfoglycolipid, the receptor for Ureaplasma spp., is localised within the 300 
amnion suggesting that the chorioamnion may have selected for adherent ureaplasma sub-301 
types in our study, although this remains to be confirmed.  302 
It is remarkable that identical variant populations were expanded within the chorioamnion of 303 
all experimentally-infected animals. However, similar findings were previously reported for 304 
other microorganisms. In an in vitro model of Escherichia coli evolution, two populations 305 
derived from a common ancestor were propagated for 20, 000 generations in minimal 306 
medium [51]. Identical changes in gene expression were detected in the two independently 307 
propagated E. coli populations relative to the ancestral strain, demonstrating parallel 308 
evolution and/or selection. In vivo selection of variant populations of Burkholderia 309 
pseudomallei has also been demonstrated. Complete genome sequencing of human B. 310 
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pseudomallei stains isolated: (i) during primary infection and (ii) following relapse of the 311 
primary infection [52] or from persistent asymptomatic carriage [53] showed that strong 312 
selection of genetic variants occurred during chronic infection. Tissue-specific selection has 313 
also been reported for Pseudomonas aeruginosa and Staphylococcus aureus colonising the 314 
lungs of cystic fibrosis patients [54, 55]. An in silico study of the coding sequences of U. 315 
urealyticum and the related microorganisms Mycoplasma genitalium and M. pneumoniae 316 
suggested that genetic selection at the codon level for U. urealyticum and M. genitalium is 317 
most likely to be driven by environmental stimuli rather than phylogenetic relationships [56]. 318 
Here, we provide evidence that different anatomical sites may select for ureaplasma variants 319 
and thus alter the socio-microbiological structure of the bacterial population.   320 
Although chorioamnion ureaplasma isolates demonstrated significant genetic variability 321 
within domain V of the 23S rRNA gene, these isolates were not phenotypically resistant to 322 
erythromycin, azithromycin or roxithromycin. Heterogeneity was observed in the MICs of 323 
roxithromycin when tested against ureaplasmas isolated from the chorioamnion, with MIC 324 
values ranging from 0.13 – 5.33 mg/L. Despite this, according to recently defined CLSI 325 
breakpoints, MICs ≤4 mg/L indicate susceptibility, whereas MICs ≥16 mg/mL indicate 326 
resistance to macrolide antimicrobials. Therefore, none of the tested isolates were resistant to 327 
the tested macrolides. We also tested the ability of chrorioamnion ureaplasma isolates to form 328 
biofilms in vitro; however, biofilm formation was not associated with increased resistance to 329 
the erythromycin, azithromyin or roxithromycin, compared to planktonic chorioamnion 330 
ureaplasma isolates (data not shown). Nucleotides that were previously associated with 331 
macrolide resistance in ureaplasmas [21, 22] remained conserved in all tested strains, 332 
potentially explaining why ureaplasmas isolated from the chorioamnion were susceptible to 333 
macrolides. It is surprising that such significant changes in the sequence of domain V of the 334 
23S rRNA gene were not associated with increased resistance to macrolides, due to potential 335 
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changes in the secondary structure of the rRNA. Furthermore, we did not observe any 336 
differences in growth rates between ureaplasma isolates containing the wild type rRNA 337 
sequence and those with the variant rRNA sequence (data not shown), suggesting that genetic 338 
variability within 23S rRNA did not affect ureaplasmal fitness. This is in agreement with 339 
Asai et al. [57] who reported that following inactivation of all seven E. coli chromosomal 340 
rRNA operons and insertion of foreign rRNA operons derived from Salmonella typhimurium 341 
or Proteus vulgaris, no effects on microbial fitness were observed. Collectively, these data 342 
demonstrate that bacteria may swap fragments or entire rRNA operons via HGT without 343 
significant impact on survival.  344 
We also performed PCR for the amplification of macrolide resistance genes including 345 
erm(B), msr(A), msr(B), msr(C) and msr(D). Previously, Lu et al. [23] characterised 346 
macrolide and lincosamide resistant ureaplasma strains and reported that ureaplasmas 347 
harbouring the erm(B) gene were associated with erythromycin MICs ranging from 8 - ≥128 348 
mg/L. The presence of erm(B) was also significantly associated with the int-Tn gene, which 349 
is a genetic marker of a transposon, and it was suggested that erm(B) may be part of a 350 
ureaplasmal transposon. Here, we detected erm(B) in isolate 442S and all chorioamnion 351 
ureaplasma isolates, but not in any ureaplasmas isolated from the amniotic fluid. This 352 
provides further evidence that a variant ureaplasma population within isolate 442S was 353 
selected for within the chorioamnion. In contrast to Lu et al., in our study erm(B) was not 354 
associated with phenotypic resistance to macrolides. We also detected msr(D) in isolate 442S, 355 
40% of amniotic fluid ureaplasmas and 100% of chorioamnion ureaplasmas. Similar to 356 
previous findings in which msr(D) was associated with very wide MIC ranges and did not 357 
always confer a resistant phenotype [23], our data demonstrated that the presence of msr(D) 358 
was not associated with macrolide resistance. Interestingly, the msr(D) PCR produced 359 
additional faint bands in chorioamnion ureaplasma isolates that were not present in amniotic 360 
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fluid ureaplasmas or isolate 442S. We were unable to identify these bands; however, we 361 
speculate that the genetic changes selected for in chorioamnion ureaplasmas may contain  362 
multiple msr(D) primer binding sites that are not present in the amniotic fluid isolates or the 363 
inoculum strain. Further research is required to characterise the role of the erm and msr genes 364 
in ureaplasmas.  365 
A limitation of our study is that ureaplasmas were injected directly into the amniotic fluid of 366 
pregnant sheep, therefore the model does not represent the progression of an ascending 367 
invasive infection from the lower genital tract, which is predicted to be a common  368 
mechanism of intra-amniotic infection. Ascending infections occur when vaginal 369 
microorganisms cross the cervix, ascend into the choriodecidual space, and then cross the 370 
chorioamnion and enter the amniotic fluid [58]. However, upper genital tract infections may 371 
also arise due to iatrogenic needle contamination at the time of amniocentesis or chronic 372 
villus sampling or haematogenous spread through the placenta [58]. Furthermore, 373 
ureaplasmas may also access the female upper genital tract by attachment to the surface of 374 
spermatozoa [44], or they may be present in the endometrium of healthy, non-pregnant 375 
females [11]. Thus ureaplasmas may colonise the amniotic fluid and chorioamnion by 376 
mechanisms other than ascending invasive infections.  377 
In summary, in vivo exposure of a non-clonal, clinical ureaplasma strain to sub-inhibitory 378 
levels of erythromycin did not induce genetic markers of macrolide resistance. However, we 379 
demonstrated significant differences between ureaplasmas isolated from the amniotic fluid 380 
and chorioamnion following chronic intrauterine infection in a sheep model, with respect to 381 
23S rRNA gene sequence and the presence of macrolide resistance genes. These findings 382 
suggest that different anatomical sites may select for variant populations within a non-clonal 383 
ureaplasma strain, and may have several implications. Firstly, the significant genetic 384 
differences between amniotic fluid ureaplasmas and chorioamnion ureaplasmas support 385 
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previous studies suggesting that ureaplasmas undergo HGT, which may result in the lateral 386 
transfer of antibiotic resistance genes, virulence genes or genes required for survival in niche 387 
environments. Secondly, the selection of variant ureaplasma subtypes at different anatomical 388 
sites suggests that intrauterine ureaplasma infections are highly complex and that amniotic 389 
fluid cultures alone may not isolate ureaplasmas that are representative of the entire 390 
population present within the fetal compartment. Clinically, this becomes important when 391 
considering antimicrobial susceptibility testing and treatment, and may explain why 392 
ureaplasma infections can be difficult to eradicate. Finally, these findings also have 393 
implications for our understanding of ureaplasmal pathogenesis, as ureaplasma subtypes 394 
localised within the chorioamnion and amniotic fluid may be associated with differences in 395 
virulence, and differences in the severity of in utero inflammation, which have been observed 396 
previously in an animal model [29, 30]. Although not examined in this study, in a previous 397 
experiment using the same inoculum strain (isolate 442S), we demonstrated that ureaplasmas 398 
isolated from the chorioamnion of pregnant sheep produced a significantly different multiple 399 
banded antigen profile compared to ureaplasmas isolated from the amniotic fluid and fetal 400 
lung [30].  This provides further evidence that the amniotic fluid and chorioamnion may 401 
select for different ureaplasma subtypes within a mixed population. The data presented in this 402 
study demonstrate that, similar to related Mycoplasmas spp., ureaplasma populations are 403 
dynamic and are influenced by the local micro-environment.  404 
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Figure Legends 
Figure 1: Significant genetic variability observed in the MH23S-11/MP23S-22 amplicon 
within domain V of the 23S rRNA gene of ureaplasmas isolated from the chorioamnion 
at 125 days gestation 
Sequence polymorphisms occurred within regions of domain V of the 23S rRNA gene 
amplified by primers MH23S-11/MP23S-22. Sequence alignment compares representative 
amniotic fluid (AF) ureaplasma isolates (n=5) and chorioamnion (CAM) ureaplasma isolates 
(n=4) from the Up and Up/E groups to the Ureaplasma parvum serovar 3 reference strain (U. 
parvum ATCC 700970, Genbank accession number AF222894) and the inoculum strain (U. 
parvum 442S). Numbering shown is U. parvum ATCC 700970 23S rRNA numbering. 
Sequences from strains AF 227 and CAM 227 have been deposited in Genbank  (accession 
numbers JF521483 and JF521484  respectively).  
 
Figure 2: Significant genetic variability observed in the MH23S-9/MP23S-23 amplicon 
within domain V of the 23S rRNA gene of ureaplasmas isolated from the chorioamnion 
at 125 days gestation 
Sequence polymorphisms occurred within regions of domain V of the 23S rRNA gene 
amplified by primers MH23S-9/MP23S-23. Sequence alignment compares representative 
amniotic fluid (AF) ureaplasma isolates (n=5) and chorioamnion (CAM) ureaplasma isolates 
(n=4) from the Up and Up/E groups to the Ureaplasma parvum serovar 3 reference strain (U. 
parvum ATCC 700970, Genbank accession number AF222894) and the inoculum strain (U. 
parvum 442S). Numbering shown is U. parvum ATCC 700970 23S rRNA numbering. 
Sequences from strains AF 227 and CAM 227 have been deposited in Genbank  (accession 
numbers JF521485 and JF521486  respectively). 
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Figure 3: Macrolide resistance genes detected in chorioamnion ureaplasma isolates  
PCR detection of erm(B) (A) and msr(D) (B) genes in ureaplasmas isolated from the amniotic 
fluid and chorioamnion of pregnant sheep after 125 days gestation. M = Molecular weight 
marker VII (Roche, Castle Hill, New South Wales); AF = amniotic fluid ureaplasma isolates; 
CAM = chorioamnion ureaplasma isolates; 442S = U. parvum strain 442S; bp = base pairs; C 
= no template negative control.  
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PRIMER TARGET AND 
NAME 
SEQUENCE (5’ – 3’) REFERENCE 
23S Domain V 
 
23SF 
23SR 
 
MH23S-11 
MP23S-22 
 
MH23S-9 
MP23S-23 
 
 
GTGAAATCCTGGTGAGGGTGA 
TTCCTACGGGCATGACAGATAG 
 
TAACTATAACGGTCCTAAGG 
GGCGACCGCCCCAGTCAAAC 
 
GCTCAACGGATAAAAGCTAC 
ACACTTAGATGCTTTCAGCG 
 
 
Dongya et al. 2008 
 
[21] 
 
 
Pereyre et al. 2007 [22] 
 
 
Pereyre et al. 2007 [22] 
23S Domain II 
 
Up23S-30 
Up23S-31 
 
TGCCTTTTGAAGTATGAGCC 
TGGCGCCATCATAGATTCAG 
 
Pereyre et al. 2007 [22] 
Ribosomal protein L4 
gene 
UpL4-U 
UpL4-R 
 
 
 
TCTATTGATGGTAACTTCGG 
GTTGAAGGTGTTTCTAAATCGC 
 
Pereyre et al. 2007 [22] 
Ribosomal protein L22 
gene 
UpL22-U 
UpL22-R 
 
 
TTCGCACCGTAAAGCTTCTC 
GTTCTGGATCAACGTTTTCG 
 
 
 
Pereyre et al. 2007 [22] 
erm(B) 
 
GAAAAGGTACTCAACCAAATA 
AGTAACGGTACTTAAATTGTTTAC 
Graham et al. 2009 [39] 
msr(A) 
 
GGCACAATAAGAGTGTTTAA 
AAGTTATATCATGAATAGATTGTCCTGTT 
Lina et al. 1999 [40] 
msr(B) 
 
TATGATATCCATAATAATTATCCAATC 
AAGTTATATCATGAATAGATTGTCCTGTT 
Lina et al. 1999 [40] 
msr(C) 
 
AAGGAATCCTTCTCTCTCCG 
GTAAACAAAATCGTTCCCG 
Lu et al. 2010 [23] 
msr(D) 
 
TTGGACGAAGTAACTCTG 
GCTTGGCTCTTACGTTC 
Daly et al. 2004 [38] 
 
Table 1: PCR primers used for the amplification and sequencing of the 23S rRNA gene and 
ribosomal protein genes; and the detection of macrolide resistance genes.  
30 
 
 Region amplified by MH23S-
11/MP23S-22 PCR primers 
Region amplified by MH23S-
9/MP23S-23 PCR primers 
Amniotic 
fluid 
ureaplasmas
§
 
Chorioamnion 
ureaplasmas 
Amniotic 
fluid 
ureaplasmas
§
 
Chorioamnion 
ureaplasmas 
Number of 
polymorphisms 
compared to 442S
ǂ
 
0/230 
nucleotides 
72/230 
nucleotides 
0/200 
nucleotides 
36/200 
nucleotides 
Number of insertions 
compared to 442S
ǂ
 
0/230 
nucleotides 
5/230 
nucleotides 
0/200 
nucleotides 
0/200 
nucleotides 
Number of deletions 
compared to 442S
ǂ
 
0/230 
nucleotides 
5/230 
nucleotides 
0/200 
nucleotides 
0/200 
nucleotides 
Percentage sequence 
similarity to 442S
ǂ
 
100% 64.3% 100% 82.0% 
G+C content 44% 52% 52% 56% 
A+T content 56% 48% 48% 44% 
 
Table 2: Significant genetic variability was detected within regions of domain V of the 23S 
rRNA gene of ureaplasmas isolated from the chorioamnion of pregnant sheep after 125 days 
gestation. 
ǂ
The number of polymorphisms, insertions, deletions and percentage sequence 
similarity were calculated relative to the inoculum strain for this study, U. parvum serovar 3 
isolate 442S. 
§
No genetic variability was observed in amniotic fluid ureaplasma isolates when 
compared to isolate 442S or U. parvum serovar 3 ATCC 700970. 
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  AMNIOTIC 
FLUID ISOLATES 
CHORIOAMNION 
ISOLATES 
ANIMAL 
NUMBER 
TREATMENT 
GROUP 
MIC (mg/L) MIC (mg/L) 
ERY AZM ROX ERY AZM ROX 
229 Up 0.33 0.50 0.17 0.25 0.25 5.33 
230 Up 0.08 0.50 0.06 - - - 
231 Up 0.17 0.13 0.13 0.13 0.06 0.67 
232 Up 0.08 0.33 0.50 0.06 0.06 0.25 
233 Up 0.35 0.25 0.50 - - - 
234 Up 0.33 0.33 0.50 0.25 0.25 0.50 
MIC50 0.17 0.33 0.17 0.13 0.06 0.50 
MIC90 0.33 0.50 0.50 0.25 0.25 0.67 
222 Up/E 0.17 0.33 0.50 - - - 
223 Up/E 0.13 0.50 0.50 - - - 
225 Up/E 0.13 0.13 0.13 0.06 0.13 0.13 
226 Up/E 0.25 0.29 0.34 0.06 0.17 4.00 
227 Up/E 0.63 0.72 0.83 0.13 0.10 2.67 
228 Up/E 0.25 1.00 0.42 0.08 0.06 0.13 
MIC50 0.17 0.33 0.42 0.06 0.10 0.13 
MIC90 0.25 0.72 0.50 0.08 0.13 2.67 
 
Table 3: MIC values of erythromycin (ERY), azithromycin (AZM) and roxithromycin 
(ROX) against amniotic fluid and chorioamnion ureaplasma isolates. Up = ureaplasma group; 
Up/E = ureaplasma + erythromycin group; dash (-) indicates samples which were ureaplasma 
culture negative after 125 days gestation.  
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